Duchenne muscular dystrophy-associated cardiomyopathy: advances in diagnosis and management
- 1Department of Neurology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Children and Adolescents' Health and Diseases/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing 400014, China
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder in which cardiac involvement is relatively insidious, and heart failure has become one of the major determinants of prognosis. Cardiac magnetic resonance imaging and speckle-tracking echocardiography provide a basis for the precise assessment of DMD-associated cardiomyopathy. At present, glucocorticoid therapy and cardiovascular drug therapy are the basic treatment approaches, and gene therapy, cell therapy, and molecularly targeted drugs are continually evolving. This review summarizes pathogenic mechanisms, diagnostic techniques, and therapeutic strategies for DMD-associated cardiomyopathy, with the aim of informing standardized clinical management and improving patient quality of life.
Related
- Case Report: Twelve-year longitudinal CMR follow-up in Becker muscular dystrophy–associated cardiomyopathy
- Chronic Inflammation, Fibrotic Remodeling, and Regenerative Failure in Duchenne Muscular Dystrophy: Mechanisms and Therapeutic Opportunities
- Clinical Trial Landscape of Duchenne Muscular Dystrophy in Europe: A 10-Year Retrospective Analysis
- Structural engineering of dual-targeting antisense oligonucleotides enhances exon 44 skipping for treating Duchenne muscular dystrophy
- Human and zebrafish data corroborate gene x gene interactions in ameliorating Duchenne muscular dystrophy disease progression
BibTeX
@article{jie2026duchenne,
title = {{Duchenne muscular dystrophy-associated cardiomyopathy: advances in diagnosis and management}},
author = {GU Jie and LIU Yu-Hang and HONG Si-Qi},
journal = {中国当代儿科杂志},
year = {2026},
month = oct,
doi = {10.7499/j.issn.1008-8830.2606154},
url = {https://doi.org/10.7499/j.issn.1008-8830.2606154},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Duchenne muscular dystrophy-associated cardiomyopathy: advances in diagnosis and management
AU - GU Jie
AU - LIU Yu-Hang
AU - HONG Si-Qi
PY - 2026
DA - 2026/10/23
JO - 中国当代儿科杂志
DO - 10.7499/j.issn.1008-8830.2606154
UR - https://doi.org/10.7499/j.issn.1008-8830.2606154
AB - Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder in which cardiac involvement is relatively insidious, and heart failure has become one of the major determinants of prognosis. Cardiac magnetic resonance imaging and speckle-tracking echocardiography provide a basis for the precise assessment of DMD-associated cardiomyopathy. At present, glucocorticoid therapy and cardiovascular drug therapy are the basic treatment approaches, and gene therapy, cell therapy, and molecularly targeted drugs are continually evolving. This review summarizes pathogenic mechanisms, diagnostic techniques, and therapeutic strategies for DMD-associated cardiomyopathy, with the aim of informing standardized clinical management and improving patient quality of life.
SN - 1008-8830
SN - 2096-9228
ER -